Will New Biotech Breakthroughs Revolutionise Early Cancer Detection in the UK?

1 min read

Key Takeaways

  • Base Genomics, an epigenetics company focusing on developing blood tests for early-stage cancer and minimal residual disease, is set to revolutionise early cancer detection in the UK.
  • The company uses TAPS (TET-assisted pyridine borane sequencing), a novel technology that avoids DNA degradation and cuts sequencing costs.
  • By preserving sequence complexity, simultaneous epigenetic and genetic analysis becomes possible, differentiating Base Genomics in the biotech industry.
  • The industry can expect significant advancements in early cancer detection, leading to improved survival rates and treatment plans.
Early cancer detection significantly improves chances of successful treatment and survival. A promising UK startup, Base Genomics, seeks to revolutionise this crucial stage of cancer management. Based in Oxford, this life science company focuses on developing a blood test for early-stage cancer and minimal residual disease by utilising a groundbreaking invention called TAPS.

TAPS, or TET-assisted pyridine borane sequencing, is an innovative approach that sequences DNA methylation. Developed at the Ludwig Institute for Cancer Research Branch at the University of Oxford, this technology offers unprecedented potential for early cancer detection and could change the biotech industry’s landscape.

What sets Base Genomics apart is that in contrast to the conventional bisulfite sequencing, TAPS does not degrade DNA. Bonus is that more DNA is available for sequencing. In addition to preserving DNA, it also retains sequence complexity while substantially cutting sequencing costs.

Due to the preservation of sequence complexity, TAPS enables simultaneous epigenetic and genetic analysis, broadening the possibilities for cancer research and developing targeted treatment strategies. This differentiation not because it is novel but also because it addresses significant challenges posed by existing methodologies.

Read more from UKT News:  Can Innovative Podcast Solutions Revolutionise Content Marketing and Broadcasting Industry?
The future for Base Genomics appears bright, promising a significant impact in the biotech industry, especially in improving early cancer detection. The potential of TAPS to offer profound insights into genetic and epigenetic shifts in early-stage cancer can open new frontiers in targeted therapy, thus increasing survival rates and improving patient care quality.

Apart from its innovative approach, Base Genomics is also contributing to the life science industry innovation ecosystem. The future of this industry is expected to benefit from the advancements offered by this promising startup. To find out more, you can visit their website, follow them on Twitter, like their Facebook page or check out their profile on Linkedin.

Want to supercharge your brand’s visibility within the UK tech industry? Reach startup founders, investors, and C-level executives with sponsored articles on UKT.news. Connect with us and discover how our advertising solutions can propel your brand to new heights. Explore our Sponsored Articles & Partnerships Program here.

Read more from UKT News:  Can AI Lead a Revolution in Fintech Consulting and Financial Services?

UKT News

UKT.news is a media platform owned by Unstructured Media, providing the latest news and insights on UK technology and startup scenes. The website offers readers with daily updates on the latest industry developments, as well as featuring exciting startups and advertising opportunities.

Leave a Reply

Your email address will not be published.